Syncom Formulations (India) Ltd. is a key player in the pharmaceutical sector, known for its innovative products and cost-effective solutions. With a current share price of ₹20.12, the company holds promise for future growth. Here’s an in-depth analysis of its share price predictions from 2024 to 2040.
About Syncom Formulations
Syncom Formulations is an Indian pharmaceutical company specializing in manufacturing and marketing formulations across various therapeutic segments. It serves both domestic and international markets, focusing on affordability and quality.
Company Details
Founded: 1988
Headquarters: Indore, Madhya Pradesh, India
Sector: Pharmaceuticals
Products: Tablets, Capsules, Syrups, Ointments
Market Reach: India and Exports
Promoter Details
Promoter Name
Holding (%)
Institutional Investors
12.50
Retail & Others
87.50
Syncom Formulations Share Price Target 2024
Growth Factors:
Expanding export markets.
Focus on affordable healthcare products.
Minimum Target: ₹22
Maximum Target: ₹25
Syncom Formulations Share Price Target 2025
Key Drivers:
Increased investment in R&D for new formulations.
Growth in the domestic healthcare sector.
Minimum Target: ₹28
Maximum Target: ₹32
Syncom Formulations Share Price Target 2026 to 2030
Year
Minimum Target (₹)
Maximum Target (₹)
2026
35
40
2027
42
48
2028
50
58
2029
60
72
2030
75
90
Syncom Formulations Share Price Target 2035
Long-Term Catalysts:
Entry into niche therapeutic areas.
Diversification into over-the-counter (OTC) products.
Minimum Target: ₹110
Maximum Target: ₹135
Syncom Formulations Share Price Target 2040
By 2040, Syncom Formulations is expected to leverage its market presence and innovation to achieve robust growth.
Minimum Target: ₹150
Maximum Target: ₹180
Final Thoughts
Syncom Formulations has the potential to grow steadily in the coming years, driven by its focus on affordable medicines and international expansion. However, stock performance depends on market conditions and the company’s execution of its growth plans.
Disclaimer: Stock market investments are subject to risks. Perform thorough research or consult a financial advisor before investing. For more insights, visit moneyphobia.in!
Recent Posts
Bajaj Consumer Care Q4 results: PAT more than doubles to ₹64 crore as revenue jumps 30% YoY
Jio Financial's Q4 FY26 shows the cost of chasing scale: Revenue doubles, profits don't
Sampann Utpadan India Limited Schedules Board Meeting on April 25, 2026 for FY26 Financial Results - scanx.trade
HDFC Bank Q4 Results Date and Time: India's largest private bank to release quarterly earnings, cash reward in Q4 - Check timeline - ET Now
Q4 result: Jio Financial, Bajaj Consumer Care, Aditya Birla Money on Apr 17 - Business Standard
Infosys Q4 results schedule out: Check date, timing, & other details - Upstox
Wendt (India) Limited Schedules Board Meeting for April 24, 2026 to Approve FY26 Results and Final Dividend - scanx.trade
Wipro Q4 results: IT stock in focus ahead of quarterly results, buyback announcement - India TV News
Indian Stocks Climb on Peace Hopes; Wipro, HDB Financial Results in Focus - Whalesbook
Dividend, Share Buyback in Q4 results 2026: Double delight by THIS BSE 500 stock; board meeting next week - ET Now
Indian Financial Firms: Results, Dividends Due Amid HDFC Bank Shake-up, Bajaj Acquisition - Whalesbook
Q4 result today: ICICI Prudential, Den Networks among 8 firms on April 14 - Business Standard